As reported on PharmaBiz, a new study published in Cell Stem Cell highlights a promising approach to cancer immunotherapy that combines stem cell technology with personalized tumor targeting. Researchers from the University of California, San Francisco (UCSF), working in collaboration with AIVITA Biomedical, have developed a dendritic cell-based vaccine platform designed to train the immune system to recognize and attack cancer cells using antigens derived from an individual patient’s tumor.
The research describes the creation of dendritic cells from induced pluripotent stem cells (iPSCs). Dendritic cells play a critical role in immune surveillance by presenting antigens to T cells and initiating immune responses. To make the cells suitable for broader clinical use, investigators employed gene-editing techniques to eliminate markers that could provoke immune rejection, creating a renewable source of universal, ready-to-use dendritic cells.
Rather than relying on a single predefined cancer target, the scientists equipped these engineered dendritic cells with the full spectrum of tumor-associated antigens obtained from patient tumor samples. This strategy provides the immune system with a more comprehensive representation of a cancer’s unique molecular profile.
In preclinical testing, the customized dendritic cells successfully activated patient-matched T cells, enabling them to identify and destroy cancer cells derived from both hematologic malignancies and solid tumors. The approach also demonstrated the ability to slow tumor progression in animal models, supporting its potential as a therapeutic cancer vaccine.
AIVITA Biomedical played a significant role in expanding the research beyond blood cancers. The company supplied patient-specific ovarian tumor cells and corresponding immune cells collected from participants enrolled in one of its Phase 2 clinical studies. These materials were used to provide the antigenic content for the engineered dendritic cells.
Results from the ovarian cancer experiments showed enhanced T-cell activation and increased tumor-cell killing when compared with control conditions. The findings suggest that the platform may have utility across a broader range of cancers, including solid tumors, which remain a major focus of cancer immunotherapy development.
According to AIVITA leadership, the study reinforces the concept that a patient’s own tumor contains the most relevant set of antigens for generating an effective anti-cancer immune response. The company noted that the UCSF platform offers a scalable method for delivering these personalized tumor signatures using laboratory-produced dendritic cells.
Researchers also emphasized the value of presenting the immune system with an authentic and comprehensive collection of tumor antigens rather than isolated synthetic targets. This broader antigen exposure may contribute to the strong T-cell responses observed in the study.
The work received funding from multiple organizations, including the National Institutes of Health, the California Institute for Regenerative Medicine, the NIH Cancer Moonshot initiative, and several biomedical research programs at UCSF.
Founded in 2016, AIVITA Biomedical focuses on stem cell technologies and cellular therapies, developing manufacturing processes intended to support personalized treatments for cancer and other diseases. The company continues to advance immunotherapy strategies that leverage patient-specific biological information to improve therapeutic outcomes.
